CD5 CAR‑T treatment for relapsed or hard‑to‑treat T‑cell lymphoma
Official title: Project 2: CAR-T cell therapy for T cell lymphoma
Funded at Baylor College of Medicine · NIH-11178348 · Data updated 2026-11-12
This project is trying CD5‑targeted CAR‑T cell therapy, including faster off‑the‑shelf products, to help people with relapsed or refractory T‑cell lymphoma get better responses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 11, 2007 |
| Project end | August 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,269,725 |
| NIH project number | 5P50CA126752-19 |
| Project ID | NIH-11178348 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with relapsed or refractory T‑cell lymphoma who meet the trial's medical and safety criteria would be the intended candidates.
✕Less likely to help
Patients with cancers other than T‑cell lymphoma, or those who do not meet safety or organ‑function requirements for cell therapy, are unlikely to benefit from this work.
What this research studies
If I have relapsed or refractory T‑cell lymphoma, this work builds on earlier patient treatments that produced meaningful responses and aims to make those therapies stronger and easier to get. The team will use drugs during cell manufacturing to prevent harmful overactivation and preserve healthier CAR‑T cells. They will also develop CAR‑T cells from donor/HSCT sources and create banked (off‑the‑shelf) products so patients can receive treatment more quickly. Clinical studies will test these approaches to see if they improve how well and how fast patients respond.
Why it matters
Potential benefit: If successful, this could provide people with relapsed T‑cell lymphoma a more effective CAR‑T option that can be delivered faster and to more patients through banked products.
How similar studies have gone: Earlier Phase I work with autologous CD5 CAR‑T showed promising responses (about 44%), but off‑the‑shelf and manufacturing‑improvement approaches are newer and less proven.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Brenner, Malcolm K. — Baylor College of Medicine
- Study coordinator: Brenner, Malcolm K.
Related research
Other NIH-funded projects on the same topics.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
-
CD5 CAR-T therapy for T-cell lymphoma shows promise in a multi-center trial
A phase 2 study tests a CD5-targeted CAR-T cell therapy in people with relapsed or refractory T-cell lymphoma to see if it can improve outcomes.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
-
How a rare intestinal T‑cell lymphoma begins
This project will test whether losing the SETD2 gene and turning on certain cancer genes causes a rare intestinal T‑cell lymphoma and makes it more sensitive to chemotherapy for people with MEITL.
-
Understanding how IL-15 affects T-cell lymphoma in the skin
This research explores how a specific signal, called IL-15, helps T-cell lymphoma cells move to and grow in the skin, aiming to find new ways to help patients with this condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.